Senator Tammy Baldwin (D-WI) despatched letters this week to firms warning of improper Orange E book listings of patents for inhalers, following up on the FTC’s deal with potential anticompetitive hurt of improper listings. In accordance with Senator Baldwin’s letters, the recipients of the letters have been warned by the FTC in November relating to the itemizing of inhaler patents, however haven’t eliminated the patents from the Orange E book. The letters comply with an investigation launched earlier this month by the Senate Committee on Well being, Training, Labor, and Pensions (of which Senator Baldwin is a member) into the costs of inhalers.
No Comments
Leave a comment Cancel